Market Research Logo

Aradigm Corp (ARDM) - Financial and Strategic SWOT Analysis Review

Aradigm Corp (ARDM) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Aradigm Corp (Aradigm) is a specialty pharmaceutical company that develops and commercializes inhalation drugs for the prevention and treatment of severe respiratory diseases. The company's product pipeline includes Pulmaquin (ARD-3150) and Lipoquin (ARD-3100) for the treatment of non-cystic bronchiectasis (BE) and cystic fibrosis (CF); ARD-1100, liposomal ciprofloxacin for the treatment of inhalation tularemia, anthrax infections, Q fever and pneumonic plague and ARD-1600, for the prevention and treatment of respiratory and other diseases in tobacco smokers through smoking cessation. Its proprietary pulmonary drug delivery platform, AERx, is customized for the delivery of drugs to the target along with liposomal formulations. Aradigm is headquartered in Hayward, California, the US.

Aradigm Corp Key Recent Developments

Mar 23,2018: Aradigm Reports Fourth Quarter 2017 And Full Year Financial Results
Feb 09,2018: Aradigm Announces Personnel Changes
Nov 02,2017: Aradigm Announces Third Quarter 2017 Financial Results
Oct 10,2017: Aradigm Regains Compliance with NASDAQ Listing Requirements
Aug 10,2017: Aradigm Announces Second Quarter 2017 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Aradigm Corp - Key Facts
Aradigm Corp - Key Employees
Aradigm Corp - Key Employee Biographies
Aradigm Corp - Major Products and Services
Aradigm Corp - History
Aradigm Corp - Company Statement
Aradigm Corp - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Aradigm Corp - Business Description
Aradigm Corp - Corporate Strategy
Aradigm Corp - SWOT Analysis
SWOT Analysis - Overview
Aradigm Corp - Strengths
Aradigm Corp - Weaknesses
Aradigm Corp - Opportunities
Aradigm Corp - Threats
Aradigm Corp - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Aradigm Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Aradigm Corp, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Aradigm Corp, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 09, 2018: Aradigm Announces Personnel Changes
Nov 02, 2017: Aradigm Announces Third Quarter 2017 Financial Results
Oct 10, 2017: Aradigm Regains Compliance with NASDAQ Listing Requirements
Aug 10, 2017: Aradigm Announces Second Quarter 2017 Financial Results
May 15, 2017: Aradigm Announces First Quarter 2017 Financial Results
Mar 28, 2017: Aradigm Announces Fourth Quarter 2016 and Full Year Financial Results
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Aradigm Corp, Key Facts
Aradigm Corp, Key Employees
Aradigm Corp, Key Employee Biographies
Aradigm Corp, Major Products and Services
Aradigm Corp, History
Aradigm Corp, Subsidiaries
Aradigm Corp, Key Competitors
Aradigm Corp, Ratios based on current share price
Aradigm Corp, Annual Ratios
Aradigm Corp, Annual Ratios (Cont...1)
Aradigm Corp, Interim Ratios
Aradigm Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Aradigm Corp, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Aradigm Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Aradigm Corp, Performance Chart (2013 - 2017)
Aradigm Corp, Ratio Charts
Aradigm Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Aradigm Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report